Harbour BioMed nets $75M in Series B+ as first global trial gets underway
Nearly two years after drawing an $85 million Series B, Shanghai-based Harbour BioMed has announced a new large funding round.
In what they’re billing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
